年轻中高危弥漫大B细胞淋巴瘤诱导化疗联合或不联合自体移植比较
回顾性分析90例≤60岁、aa-IPI≥2分的初治DLBCL患者,比较R-CHOP、增强免疫化疗及增强免疫化疗序贯auto-HSCT的疗效。auto-HSCT组5年PFS和OS优于增强免疫化疗组,高危患者中auto-HSCT组5年PFS和OS优于单纯化疗组。
要点
- auto-HSCT组5年PFS率65.8%、OS率78.6%,高于增强免疫化疗组的55.3%和61.6%。
- 高危患者中auto-HSCT组5年PFS率62.3%、OS率69.2%,优于R-CHOP组和增强免疫化疗组。
- GCB亚型是R-CHOP组和增强免疫化疗组PFS、OS的独立预后因素,在auto-HSCT组无显著差异。
核心结论
- 增强免疫化疗序贯auto-HSCT可改善年轻初治高危DLBCL患者(特别是non-GCB亚型)的预后。
研究设计与样本
- 回顾性研究纳入90例年龄≤60岁、aa-IPI评分2或3分的初治DLBCL患者。
- R-CHOP组32例,增强免疫化疗组25例,auto-HSCT组33例。
主要发现
- R-CHOP组、增强免疫化疗组、auto-HSCT组5年PFS率分别为(33.5±10.7)%、(55.3±10.1)%、(65.8±13.6)%(P=0.012)。
- R-CHOP组、增强免疫化疗组、auto-HSCT组5年OS率分别为(49.7±9.0)%、(61.6±10.2)%、(78.6±7.8)%(P=0.035)。
- R-CHOP组与增强免疫化疗组5年PFS、OS率差异均无统计学意义(P=0.519,P=0.437);auto-HSCT组5年PFS率高于增强免疫化疗组(P=0.042)。
- 高危患者中auto-HSCT组(26例)5年PFS率(62.3±14.3)%、OS率(69.2±13.9)%,高于R-CHOP组(20例)的(41.1±13.5)%、(51.5%±14.0)%和增强免疫化疗组(17例)的(21.9±11.6)%、(35.4±13.6)%(P=0.002,P=0.019)。
- auto-HSCT组高危患者与R-CHOP组低危患者(12例)、增强免疫化疗组低危患者(8例)的5年PFS率分别为(62.3±14.3)%、(58.3±18.6)%、(51.4±18.7)%(P=0.686),5年OS率分别为(69.2±13.9)%、(62.5±15.5)%、(58.3±18.6)%(P=0.592)。
关键数值与推荐
- R-CHOP组GCB亚型(16例)3年PFS、OS率均高于non-GCB亚型(16例)(P=0.030,P=0.041)。
- 增强免疫化疗组GCB亚型(12例)3年PFS、OS率均高于non-GCB亚型(13例)(P=0.044,P=0.047)。
- auto-HSCT组GCB亚型(15例)与non-GCB亚型(18例)3年PFS、OS率差异均无统计学意义(P=0.199,P=0.093)。
- 多因素分析:R-CHOP组PFS的HR=0.274(95%CI 0.094~0.800),P=0.018;OS的HR=0.408(95%CI 0.164~1.015),P=0.045。
- 多因素分析:增强免疫化疗组PFS的HR=0.423(95%CI 0.043~1.152),P=0.048;OS的HR=5.758(95%CI 0.882~6.592),P=0.035。
临床怎么用
- 作者认为,增强免疫化疗序贯auto-HSCT可改善年轻初治高危DLBCL患者(特别是non-GCB亚型)的预后。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the efficacy of induction chemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) for newly diagnosed young diffuse large B cell lymphoma (DLBCL) patients. Methods: The retrospective study was performed in 90 cases of young patients (≤60 years) with newly diagnosed DLBCL and an age-adjusted International Prognostic Index (aa-IPI) score of 2 or 3. All of them were treated with R-CHOP (32 cases, rituximab combined with CHOP), dose-intensive regimens (DA-EPOCH, Hyper CVAD/MA or ESHAP) combined with or without rituximab (25 cases), and consolidated with up-front auto-HSCT (33 cases), respectively. The efficacy and the potential predictors were evaluated. Results: ①The median age of 90 patients was 43 (18-60) years old. The median follow-up time was 42 (3-110) months. ②The 5-year progression-free survival (PFS) for R-CHOP group, dose-intensive chemotherapy group and auto-HSCT group were (33.5±10.7) %, (55.3±10.1) % and (65.8±13.6) % (P=0.012), the 5-year overall survival (OS) were (49.7±9.0) %, (61.6±10.2) % and (78.6±7.8) % (P=0.035), respectively. There was no significant difference in 5-years PFS and OS between the R-CHOP group and dose-intensive chemotherapy group (P=0.519, P=0.437) compared with that of the dose-intensive chemotherapy group, auto-HSCT group has higher 5-year PFS (P=0.042). ③ When stratified with IPI score, the high-risk group treated with auto-HSCT (26 cases) showed similar 5-years PFS and 5-years OS to those in the low-risk group with chemotherapy alone (12 cases were in R-CHOP group and 8 cases were in dose-intensive chemotherapy group) [5-years PFS were (62.3 ±14.3)%, (58.3 ±18.6)% and (51.4±18.7)%, respectively, P=0.686; 5-years OS were (69.2±13.9)%, (62.5±15.5)% and (58.3±18.6)%, respectively, P=0.592]. ④However, the high-risk group treated with auto-HSCT (26 cases) showed superior 5-years PFS (P=0.002) and 5-years OS (P=0.019) compared to the high-risk group with chemotherapy alone (20 cases were in R-CHOP group and 17 cases were in dose-intensive chemotherapy group) [5-years PFS were (62.3±14.3)%, (41.1±13.5)% and (21.9±11.6)%, respectively; 5-years OS were (69.2±13.9)%, (51.5%±14.0)% and (35.4±13.6)%, respectively]. ⑤In the univariate analysis, as a whole, patients diagnosed with GCB subtype had higher 3-years PFS (P=0.022) and 3-years OS (P=0.037) compared to non-GCB subtype patients; in subgroup analysis, patients diagnosed with GCB subtype had higher 3-years PFS and 3-years OS compared to non-GCB subtype both in R-CHOP group (P=0.030, P=0.041) and dose-intensive chemotherapy group (P=0.044, P=0.047), but not in auto-HSCT group (P=0.199, P=0.093). ⑥In the multivariate analysis, different molecular classification (GCB/non-GCB) was an independent predictor for PFS and OS both in R-CHOP group [HR=0.274 (95% CI 0.094-0.800), P=0.018; HR=0.408 (95% CI 0.164-1.015), P=0.045] and dose-intensive chemotherapy group [HR=0.423 (95% CI 0.043-1.152), P=0.048; HR=5.758 (95% CI 0.882-6.592), P=0.035]. However, there was no significant difference in PFS and OS for auto-HSCT group between GCB/non-GCB patients. Conclusion: Induction chemotherapy followed by up-front auto-HSCT has significant effect on efficacy for young and untreated patients with high risk DLBCL. Combined with induction chemotherapy followed by up-front auto-HSCT could improve the prognosis of non-GCB patients. 目的: 比较诱导化疗联合或不联合自体造血干细胞移植(auto-HSCT)治疗初治年轻弥漫大B细胞淋巴瘤(DLBCL)患者的疗效。 方法: 回顾性分析90例年龄≤60岁、年龄调整的国际预后指数(aa-IPI)≥2分的初治DLBCL患者的临床资料,根据治疗方案将患者分为R-CHOP组(32例,利妥昔单抗联合CHOP方案化疗)、增强免疫化疗组(25例,利妥昔单抗联合EPOCH、Hyper-CVAD/R-MA或ESHAP方案化疗)和auto-HSCT组(33例,增强免疫化疗序贯auto-HSCT),进行疗效及相关预后因素分析。 结果: ①90例患者中男40例(44.4%)、女50例(55.6%),中位年龄43(18~60)岁,中位随访时间42(3~110)个月。②R-CHOP组、增强免疫化疗组、auto-HSCT组5年无进展生存(PFS)率分别为(33.5±10.7)%、(55.3±10.1)%、(65.8±13.6)%(P=0.012),5年总生存(OS)率分别为(49.7±9.0)%、(61.6±10.2)%、(78.6±7.8)%(P=0.035)。R-CHOP组与增强免疫化疗组比较,5年PFS、OS率差异均无统计学意义(P=0.519,P=0.437);auto-HSCT组5年PFS率高于增强免疫化疗组(P=0.042)。③auto-HSCT组IPI分层高危患者(26例)、R-CHOP组低危患者(12例)、增强免疫化疗组低危患者(8例)的5年PFS率分别为(62.3±14.3)%、(58.3±18.6)%、(51.4±18.7)%(P=0.686),5年OS率分别为(69.2±13.9)%、(62.5±15.5)%、(58.3±18.6)%(P=0.592)。④高危患者比较,auto-HSCT组(26例)较R-CHOP组(20例)、增强免疫化疗组(17例)有更高的5年PFS率[(62.3±14.3)%、(41.1±13.5)%、(21.9±11.6)%,P=0.002]和5年OS率[(69.2±13.9)%、(51.5%±14.0)%、(35.4±13.6)%,P=0.019]。⑤R-CHOP组生发中心来源(GCB)亚型(16例)患者3年PFS、OS率均高于非生发中心来源(non-GCB)亚型患者(16例)(P=0.030,P=0.041);增强免疫化疗组GCB亚型患者(12例)3年PFS、OS亦高于non-GCB亚型患者(13例)(P=0.044,P=0.047);auto-HSCT组GCB亚型(15例)、non-GCB亚型患者(18例)3年PFS、OS率差异均无统计学意义(P=0.199,P=0.093)。⑥多因素结果分析显示,细胞来源(GCB/non-GCB)是影响R-CHOP组[PFS:HR=0.274(95% CI 0.094~0.800),P=0.018;OS:HR=0.408(95% CI 0.164~1.015),P=0.045]和增强免疫化疗组[PFS:HR=0.423(95% CI 0.043~1.152),P=0.048;OS:HR=5.758(95%CI 0.882~6.592),P=0.035]PFS率、OS率的独立预后因素,但不是影响auto-HSCT组PFS率、OS率的独立预后因素。 结论: 增强免疫化疗序贯auto-HSCT可改善年轻初治高危DLBCL患者(特别是non-GCB亚型)的预后。.
引用
- Wang X, Xia B, Wang CY, et al. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 30831626. doi:10.3760/cma.j.issn.0253-2727.2019.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。